Development of a Directly Observed Therapy Adherence Intervention for Adolescents with Human Immunodeficiency Virus-1: Application of Focus Group Methodology to Inform Design, Feasibility, and Acceptability

Journal of Adolescent Health

Volumn 44, Issue 2, 2009, Pages 124-132

  Garvie, Patricia A ^a,b   Lawford, Joanne ^a   Flynn, Patricia M ^a,b   Gaur, Aditya H ^a   Belzer, Marvin ^c   McSherry, George D ^d   Hu, Chengcheng ^e,f  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adherence; Adolescents; Focus group; HIV; Modified directly observed therapy (MDOT)

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CODING; COMMUNITY CARE; DIRECTLY OBSERVED THERAPY; ETHNOGRAPHY; FEASIBILITY STUDY; FEEDBACK SYSTEM; FEMALE; GROUPS BY AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; METHODOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRIVACY; UNITED STATES; VALIDATION PROCESS;

ADOLESCENT; ATTITUDE TO HEALTH; DIRECTLY OBSERVED THERAPY; FEASIBILITY STUDIES; FEMALE; FOCUS GROUPS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; PRIVACY; QUESTIONNAIRES; UNITED STATES; YOUNG ADULT;

EID: 58649098328     PISSN: 1054139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jadohealth.2008.05.006     Document Type: Article

References (39)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report (2002) 14:1-40
2. Belzer M.E., Fuchs D.N., Luftman G.S., et al. Antiretroviral adherence issues among HIV-positive adolescents and young adults. J Adolesc Health 25 (1999) 316-319
3. Kelly J.A., Otto-Salaj L.L., Sikkema K.J., et al. Implications of HIV treatment advances for behavioral research on AIDS protease inhibitors and new challenges in HIV secondary prevention. Health Psychol 17 (1998) 310-319
4. Wainberg M.A., and Friedlan G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279 (1998) 1977-1983
5. Singh N., Berman S.M., Swindells S., et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 29 (1999) 824-830
6. Paterson D.L., Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133 (2000) 21-30
7. Chow R., Chin T., Fong I.W., et al. Medication use patterns in HIV-positive patients. Can J Hosp Pharmacol 46 (1993) 171-175
8. Singh N., Squier C., Sivek C., et al. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance. AIDS Care 8 (1996) 261-269
9. Martinez J., Bell D., Camacho R., et al. Adherence to antiviral drug regimens in HIV-infected adolescent patients engaged in care in a comprehensive adolescent and young adult clinic. JAMA 92 (2000) 55-62
10. Murphy D.A., Wilson C.M., Durako S.J., et al. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 13 (2001) 27-40
11. Flynn P.M., Rudy B.J., Douglas S.D., et al. Virologic and immunologic outcome after 24 weeks in HIV-1 infected adolescents on highly active antiretroviral therapy. J Infect Dis 190 (2004) 271-279
12. Bailey A., Ferguson E., and Voss S. Factors affecting an individual's ability to administer medication. Home Healthcare Nurse 13 (1995) 57-63
13. Haynes R.B. Compliance on Health Care. In: Haynes R.B., Taylor D.W., and Sackett D.L. (Eds). Strategies to improve compliance with referrals, appointments, and prescribed medical regimens (1979), Johns Hopkins University Press, Baltimore, MD 121-143
14. Meichenbaum D., and Turk D.C. Treatment adherence: Terminology, incidence, and conceptualization. In: Meichenbaum D. (Ed). Facilitating Treatment Adherence: A Practitioner's Guidebook (1987), Plenum Press, New York 19-39
15. Carney R.M., Freedland K.E., Eisen S.A., Rich M.W., et al. Major depression and medication adherence on elderly patients with coronary artery disease. Health Psychol 14 (1995) 88-90
16. Chesney M., Folkman S., and Chambers D. Coping effectiveness training for men living with HIV: Preliminary findings. Int J STD AIDS 7 (1996) 75-82
17. Lucas G.M., Chaisson R.E., and Moore R.D. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 131 (1999) 81-87
18. Chaulk C.P., and Kazandjian V.A. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA 279 (1998) 943-948
19. Centers for Disease Control and Prevention. Improving Patient Adherence to Tuberculosis Treatment (1994), Centers for Disease Control and Prevention, US Department of Health and Human Services, Public Health Service, Atlanta, GA
20. Behforouz H.L., Farmer P.E., and Mukherjee J.S. From directly observed therapy to accompagnateurs: Enhancing AIDS treatment outcomes in Haiti and in Boston. Clin.Infect Dis S429 (2004) 36
21. Goggin K., Liston R.J., and Mitty J.A. Modified directly observed therapy for antiretroviral therapy: A primer from the field. Public Health Rep 122 (2007) 472-481
22. Myung P., Pugatch D., Brady M.F., et al. Directly observed highly active antiretroviral therapy for HIV-infected children in Cambodia. Am J Public Health 97 (2007) 974-977
23. Garland W.H., Wohl A.R., Valencia R., et al. The acceptability of a directly-administered antiretroviral therapy (DAART) intervention among patients in public HIV clinics in Los Angeles, California. AIDS Care 19 (2007) 159-167
24. Macalino G.E., Hogan J.W., Mitty J.A., et al. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS 21 (2007) 1473-1477
25. Altice F.L., Maru D.S., Bruce R.D., et al. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: A prospective, randomized, controlled trial. Clin Infect Dis 45 (2007) 770-778
26. Pearson C.R., Micek M.A., Simoni J.M., et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr 46 (2007) 238-244
27. Babudieri S., Aceti A., D'Offizi G.P., et al. Directly observed therapy to treat HIV infection in prisoners. JAMA 284 (2000) 179-180
28. Kirkland L.R., Fischl M.A., Tashima K.T., et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis (2002) 511-518
29. Wohl D.A., Stephenson B.L., Golin C.E., et al. Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Clin Infect Dis (2003) 1572-1576
30. Clarke S., Keenan E., Ryan M., et al. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Read (2002) 305-306
31. Conway B., Prasad J., Reynolds R., et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis (2004) S402-S408
32. Lucas G.M., Weidle P.J., Hader S., and Moore R.D. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: A nonrandomized comparative study. Clin Infect Dis (2004) S409-S413
33. Mitty J.A., McKenzie M., Stenzel M., et al. Modified directly observed therapy for treatment of human immunodeficiency virus. JAMA 282 (1999) 1334
34. Wohl A., Garland W.H., Squires K., et al. The feasibility of a community-based directly administered antiretroviral therapy program. Clin Infect Dis 38 Suppl 5 (2004) S388-S392
35. Wohl A.R., Garland W.H., Valencia R., et al. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clin Infect Dis 42 (2006) 1619-1627
36. Mostashari F., Riley E., Selwyn P., et al. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J Acquir Immune Defic Syndr Hum Retroviral 18 (1998) 341-348
37. Murphy D.A., Moscicki A.B., Vermund S.H., et al. Psychological distress among HIV+ adolescents in the REACH study: Effects of life stress, social support, and coping. The Adolescent Medicine HIV/AIDS Research Network. J Adolesc Health (2000) 391-398
38. Pao M., Lyon M., D'Angelo L.J., et al. Psychiatric diagnosis in adolescents seropositive for the human immunodeficiency virus. Arch Pediatr Adoles Med 154 (2000) 240-244
39. Rich M., and Ginsburg K.R. The reason and rhyme of qualitative research: Why, when, and how to use qualitative methods in the study of adolescent health. J Adolesc Health 25 (1999) 371-378